Baxter International Inc.
| NYSE: BAX | Healthcare / Medical Instruments & Supplies / USA |
| 82.69 | -0.4100 | -0.49% | Vol 1 445 444 | 1Y Perf 10.09% |
| Jul 22nd, 2019 16:01 |
| BID | 0.0000 | ASK | 0.0000 | ||
| Open | 83.32 | Previous Close | 83.10 | ||
| Pre-Market | 83.30 | After-Trading | 82.78 | ||
| 0.20 0.24% | 0.09 0.11% |
| Target Price | 81.57 | Analyst Rating | Moderate Buy 1.83 | |
| Potencial % | -1.35 | Finscreener Ranking | ★+ 43.19 | |
| Insiders Trans % 3/6/12M | -100/-100/-100 | Value Ranking | ★+ 44.31 | |
| Insiders Value % 3/6/12M | -100/-100/-100 | Growth Ranking | ★★★★ 57.48 | |
| Insiders Shares Cnt. % 3/6/12M | -100/-100/-100 | Income Ranking | ★+ 36.19 | |
| Market Cap (mil) | 42 186 | Earnings Rating | Strong Buy | |
| Price Range Ratio 52wk % | 94.58 | Earnings Date | 25th Jul 2019 |
Today's Price Range 82.5383.39 | 52wk Range 61.0583.93 | 5 Year PE Ratio Range 4.9060.80 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.76% | ||
| 1 Month | 0.34% | ||
| 3 Months | 8.32% | ||
| 6 Months | 18.74% | ||
| 1 Year | 10.09% | ||
| 3 Years | 79.02% | ||
| 5 Years | 104.67% | ||
| 10 Years | 230.73% |
| Management Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Return on Equity (5Y Avg) | 3.84 | |||
ROE last 12 Months | 19.86 | |||
Return on Assets (5Y Avg) | 2.00 | |||
ROA last 12 Months | 9.97 | |||
Return on Capital (5Y Avg) | 15.99 | |||
ROC last 12 Months | 13.29 | |||
Return on invested Capital Q | 3.13 | |||
Return on invested Capital Y | 13.95 | |||
Assets Turnover | 1.00 | |||
Receivables Turnover | 8.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
PE Ratio | 28.40 | |||
PB Ratio | 5.54 | |||
PS Ratio | 5.39 | |||
Price to Cash Flow | 25.00 | |||
Price to Free Cash Flow | 112.80 | |||
Cash Flow Per Share | 3.32 | |||
Price to Tangible Book | 12.95 | |||
Book Value per Share | 14.99 | |||
Enterprise Value (in ths.) | 44 736 000 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Quick Ratio | 1.10 | |||
Current Ratio | 1.80 | |||
Long Term Debt to Total Capital | 0.31 | |||
Total Debt to Equity | 0.56 | |||
Interest Coverage | 18.10 | |||
| Leverage Ratio | 2.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Gross Margin | 42.80 | |||
EBIT Margin | 15.70 | |||
EBITDA Margin | 22.80 | |||
Pre-tax Profit Margin | 18.90 | |||
Profit Margin | 15.72 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Revenue LTM (in ths.) | 7 865 000 | |||
Revenue per Share | 15.42 | |||
Revenue Growth 3 Years | -0.88 | |||
Revenue Growth 5 Years | -10.55 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Dividend Yield | 1.06 | |||
Dividend Rate | 0.88 | |||
Dividend Growth 3 Years | 0.55 | |||
Dividend Growth 5 Years | -21.65 |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2019 | 0.68 | 0.76 | 11.76 |
| Q04 2018 | 0.73 | 0.78 | 6.85 |
| Q03 2018 | 0.74 | 0.80 | 8.11 |
| Q02 2018 | 0.71 | 0.77 | 8.45 |
| Q01 2018 | 0.62 | 0.70 | 12.90 |
| Q04 2017 | 0.59 | 0.64 | 8.47 |
| Q03 2017 | 0.59 | 0.64 | 8.47 |
| Q02 2017 | 0.57 | 0.63 | 10.53 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2019 QR | 0.81 | 0.00 | - |
| 9/2019 QR | 0.85 | -2.30 | Negative |
| 12/2019 FY | 3.32 | 1.53 | Positive |
| 12/2020 FY | 3.72 | 0.54 | Positive |
| Next Report Date | 25th Jul 2019 |
| Estimated EPS Next Report | 0.81 |
| Estimates Count | 10 |
| EPS Growth Next 5 Years % | 12.80 |
| Volume Overview | |
|---|---|
| Volume | 1 445 444 |
| Shares Outstanding (in ths.) | 510 168 |
| Trades Count | 7 753 |
| Dollar Volume | 97 178 326 |
| Avg. Volume | 2 782 121 |
| Avg. Weekly Volume | 2 418 444 |
| Avg. Monthly Volume | 2 122 011 |
| Avg. Quarterly Volume | 2 398 705 |
Baxter International Inc.
Baxter manufactures medical products across seven major reported business segments. The renal segment (33% of 2018 sales) includes peritoneal dialysis and hemodialysis products for chronically ill patients while its acute therapies segment (5%) offers kidney or other organ support tools in intensive care situations. The medication delivery segment (24% of sales) sells IV pumps, administrative sets, and solutions while its nutrition segment (8% of sales) offers parenteral nutrition therapies. The pharmaceuticals segments (19% of sales) offers injectable drugs, anesthetic gases, and compounding services. The advanced surgery segment (7% of sales) provides hemostastic products and biosurgical sealants. Contract manufacturing rounds out the remaining 5% of sales.
CEO: Jose E. Almeida
Teplephone: +1 224 948-2000
Address: One Baxter Parkway, Deerfield 60015, IL, USA
